Needham Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $52
Needham analyst Ami Fadia maintains $Harmony Biosciences(HRMY.US)$ with a buy rating, and maintains the target price at $52.According to TipRanks data, the analyst has a success rate of 43.8% and a
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Harmony Biosciences Holdings (HRMY) and Keros Therapeutics (KROS)
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
Harmony Biosciences Boosted by Narcolepsy Treatment, Diversification Outlook. UBS Says
Unveiling 6 Analyst Insights On Harmony Biosciences
UBS Initiates Harmony Biosciences Holdings at Buy With $56 Price Target
UBS Initiates Harmony Biosciences(HRMY.US) With Buy Rating, Announces Target Price $56
UBS analyst Ashwani Verma initiates coverage on $Harmony Biosciences(HRMY.US)$ with a buy rating, and sets the target price at $56.According to TipRanks data, the analyst has a success rate of 45.3%
Is Harmony Biosciences (HRMY) a Great Value Stock Right Now?
Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Shares Not Telling The Full Story
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
'Bottom-fishing' Ideas Within Piper Sandler's Universe of Stocks
Surging Earnings Estimates Signal Upside for Harmony Biosciences (HRMY) Stock
Can Harmony Biosciences (HRMY) Climb 25.05% to Reach the Level Wall Street Analysts Expect?
Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (HRMY) and McKesson (MCK)
Harmony Biosciences Holdings (HRMY) Receives a Buy From Oppenheimer
Express News | Harmony Biosciences : Mizuho Raises Target Price to $42 From $40
Goldman Sachs Maintains Harmony Biosciences(HRMY.US) With Sell Rating, Announces Target Price $28
Goldman Sachs analyst Corinne Johnson maintains $Harmony Biosciences(HRMY.US)$ with a sell rating, and sets the target price at $28.According to TipRanks data, the analyst has a success rate of 55.0%
Harmony Biosciences Holdings Sell Rating Affirmed Amid Slowing Patient Growth and Unchanged Revenue Guidance
Harmony Biosciences Price Target Maintained With a $52.00/Share by Needham
Harmony Biosciences Analyst Ratings